After CDC approving Johnson & Johnson vaccine last week, vaccination sites are getting the new vaccines as early as Tuesday. On Sunday, White House officials announced that the vaccine distribution centers will start receiving 3.9 million doses of the new Johnson & Johnson COVID-19 vaccine as soon as possible. Johnson & Johnson vaccine will be the third vaccine against COVID-19 found in the country. Biden administration officials declared that nearly 4 million doses will be equally distributed this week among all states and territories, along with doses of the other two vaccines, from Pfizer and Moderna.
Johnson & Johnson Vaccines Will Be Rolled Out As Early As Tuesday
Medical experts and officials say that Johnson & Johnson vaccine is the first one that requires just one dose and it only requires one shot and is effective and safe. The Centers for Disease Control and Prevention recommended the vaccine for use in people 18 years of age and older Sunday. The CDC’s Advisory Committee on Immunization Practices (ACIP) reviewed the vaccine trial data and voted to recommend the vaccine.
The CDC Director, Dr. Rochelle P. Walensky formalized the votes and said that the new vaccine would offer more options and flexibility for the public, jurisdictions, and vaccine providers. The CDC also recommends certain people get the one-shot vaccine over existing two-shot vaccines from Pfizer and Moderna. Walensky said, “Getting vaccinated with the first vaccine available to you will help protect all of us from COVID-19”.
Johnson & Johnson vaccine is easier to transport and store
The Johnson & Johnson vaccine has many advantages over the other two vaccines such as it needs only one dose compared to the two doses for Moderna and Pfizer, it does not need to be kept in a freezer, and is easier to transport and store. But studies show that Moderna and Pfizer’s vaccines appear to be more effective than Johnson & Johnson’s showing better 94% effectiveness in trials and case studies.
On Sunday, Walensky said that “This official CDC recommendation which follows Saturday’s FDA decision to authorize emergency use of the vaccine is another milestone toward an end to the pandemic”. In clinical trials, Johnson & Johnson vaccine appeared to be 72% effective among the US trial participants and was less effective in South Africa and Latin America, where newer strains of the virus are circulating. Studies also show that Johnson & Johnson vaccine was nearly 100% effective at preventing hospitalizations and deaths. While the Pfizer-BioNTech and Moderna vaccines are 95% and 94.1% effective in preventing symptomatic illness respectively.
It is the third vaccine added to the nation’s arsenal and is a viral vector vaccine made from an inactivated adenovirus, the virus that causes the common cold, and contains a piece of DNA that instructs the body to make the COVID-19 spike protein. Dr. Lorry Rubin, director of pediatric infectious disease at Northwell Health’s Cohen Children’s Medical Center and a former ACIP member said that “The Johnson & Johnson vaccine was not compared to the Pfizer or Moderna vaccine, which in fact, were not compared to each other. These studies were done at a somewhat different time period, and we have different variants of the COVID-19 virus circulation, so it’s not really comparing apples to apples”.